B7-H7 (HHLA2) inhibits T-cell activation and proliferation in the presence of TCR and CD28 signaling

[1]  Eric O Long,et al.  CD28 Homolog Is a Strong Activator of Natural Killer Cells for Lysis of B7H7+ Tumor Cells , 2019, Cancer Immunology Research.

[2]  B. Nelson,et al.  The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity , 2018, Nature Communications.

[3]  A. Borczuk,et al.  Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1–Negative Human Lung Cancers , 2018, Clinical Cancer Research.

[4]  W. Zou,et al.  Phenotype and tissue distribution of CD28H+ immune cell subsets , 2017, Oncoimmunology.

[5]  N. Rahimi,et al.  Targeting tumor multicellular aggregation through IGPR-1 inhibits colon cancer growth and improves chemotherapy , 2017, Oncogenesis.

[6]  A. Iyer,et al.  PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome , 2017, Front. Pharmacol..

[7]  D. Altomare,et al.  Advancing Cancer Therapy with Present and Emerging Immuno-Oncology Approaches , 2017, Front. Oncol..

[8]  X. Zang,et al.  HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival , 2016, Scientific Reports.

[9]  T. Hünig,et al.  CD28 co-stimulation in T-cell homeostasis: a recent perspective , 2015, ImmunoTargets and therapy.

[10]  G. Freeman,et al.  A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2 , 2015, Clinical Cancer Research.

[11]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[12]  G. Lauvau,et al.  Mechanisms of Memory T Cell Activation and Effective Immunity. , 2015, Advances in experimental medicine and biology.

[13]  M. Curran,et al.  Immune checkpoint combinations from mouse to man , 2015, Cancer Immunology, Immunotherapy.

[14]  A. Fiser,et al.  Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein , 2014, Clinical Cancer Research.

[15]  L. Riella,et al.  Co-Inhibitory Pathways and Their Importance in Immune Regulation , 2014, Transplantation.

[16]  R. Noelle,et al.  B7 family checkpoint regulators in immune regulation and disease. , 2013, Trends in immunology.

[17]  I. Choi,et al.  Emerging Co-signaling Networks in T Cell Immune Regulation , 2013, Immune network.

[18]  J. Taube,et al.  B7-H5 costimulates human T cells via CD28H , 2013, Nature Communications.

[19]  X. Zang,et al.  HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function , 2013, Proceedings of the National Academy of Sciences.

[20]  Y. Shoenfeld,et al.  Biologic therapy for autoimmune diseases: an update , 2013, BMC Medicine.

[21]  T. Welling,et al.  T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. , 2013, Current opinion in immunology.

[22]  Lieping Chen,et al.  Molecular mechanisms of T cell co-stimulation and co-inhibition , 2013, Nature Reviews Immunology.

[23]  R. Zamoyska,et al.  T cell receptor signalling networks: branched, diversified and bounded , 2013, Nature Reviews Immunology.

[24]  N. Rahimi,et al.  Identification of IGPR-1 as a novel adhesion molecule involved in angiogenesis , 2012, Molecular biology of the cell.

[25]  Aaron J. Martin,et al.  Current landscape for T-cell targeting in autoimmunity and transplantation. , 2011, Immunotherapy.

[26]  G. Freeman,et al.  Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. , 2007, Immunity.

[27]  I. Wang,et al.  Program Death-1 Engagement Upon TCR Activation Has Distinct Effects on Costimulation and Cytokine-Driven Proliferation: Attenuation of ICOS, IL-4, and IL-21, But Not CD28, IL-7, and IL-15 Responses , 2003, The Journal of Immunology.

[28]  M. Sayegh,et al.  CTLA4-Ig: a novel immunosuppressive agent , 2000, Expert opinion on investigational drugs.

[29]  J. Ceuppens,et al.  Differences in the stimulating capacity of immobilized anti-CD3 monoclonal antibodies: variable dependence on interleukin-1 as a helper signal for T-cell activation. , 1991, Immunology.

[30]  A. Tunnacliffe,et al.  The majority of human CD3 epitopes are conferred by the epsilon chain. , 1989, International immunology.

[31]  P. Beverley,et al.  Human T lymphocyte activation by monoclonal antibodies; OKT3, but not UCHT1, triggers mitogenesis via an interleukin 2-dependent mechanism. , 1984, Journal of immunology.